News

The introduction of brolucizumab resulted in savings in the manufacturer-recommended and real-world evidence regimens.

Low luminance contrast sensitivity was significantly more reduced in nGA eyes than in eyes with drusen alone, but no differences were seen when assessing other cone functions with normal luminance CS or LLVA

A retrospective analysis of 360 individuals identified several malignancy risk factors for plaque psoriasis patients.

The mean plasma Ctrough of roflumilast was 1.78 ng/mL, and 9.86 ng/mL for roflumilast N-oxide after 8 weeks of treatment.

Tarun Sharma, MD, a rheumatologist with the Allegheny Health Network who helped author the American College of Rheumatology's most recent gout guidelines, sits down to provide perspective on the latest updates in gout from 2022, including new trial data, regulatory news and updates, and a glimpse into what he is most excited for in 2023.

An interview in which Dr. Lebwohl assessed the recent phase 3 trial data on itch treatment for psoriasis patients.

Dry AMD was more common than wet AMD, but visual acuity was more significantly affected in patients with wet AMD.

The implant significantly reduced CRT in patients with RVO-ME, but the study reported no relationship between OCT biomarkers and clinical outcomes.

Myopia progressed slower in the highly aspherical lenslet spectacle subset compared to single vision spectacles during the first 2 stages of the study.

Mixed emollients were effective in preventing infant atopic dermatitis development compared to standard care.

Research suggested no significant relationship between peanut sensitivity and AD severity as measured by two scores, although the study was acknowledged to have a smaller population due to pandemic restrictions.

The shared genetic structure and pleiotropic mechanisms in ocular diseases interprets their clinical associations to some extent, according to study authors.

New research on the TNF-alpha inhibitor infliximab as a treatment for PD-1-induced psoriasis demonstrated the treatment’s potential.

Both direct and indirect costs were higher in patients with mild-to-moderate and severe atopic dermatitis compared to the control group.

A recent analysis indicated the efficacy of 100 or 200 mg of tildrakizumab for moderate-to-severe plaque psoriasis patients.

The result show the gain in best-corrected visual acuity and the reduction in central subfield thickness at the conclusion of the core study was maintained up to week 24 of the extension study, with no differences in the safety profile.

A Q&A interview with Dr. Simpson regarding the recent INTEGUMENT clinical trial results regarding roflumilast for atopic dermatitis.

Despite its frequent use as a rescue therapy for patients with interstitial lung disease associated with connective tissue disorder, the effectiveness of rituximab hasn't been evaluated in many clinical trials.

Patients with sarcoidosis who practiced online mindfulness-based cognitive therapy (eMBCT) showed improvements in fatigue, anxiety, depression, and health status.

The findings may support the use of macular imaging for monitoring at the time of glaucoma diagnosis and for monitoring the rate of GCC thinning.

Neither the retinal disease nor the VEGF inhibitor type was significantly associated with rhegmatogenous retinal detachment risk.

The pooled proportions of virological relapse and clinical relapse after discontinuing treatment in cirrhotic patients was 55.23 and 43.56%, respectively.

Investigators aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.

Factors including trust of information, fear, and resilience were related to insomnia and suicidal thoughts in healthcare workers, general population and outpatients.

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

Enhanced ellipsoid integrity, greater outer retinal thickness, and decreased GA were associated with increased BCVA gains with risuteganib.